Idec Pharmaceuticals Corporation

Soulaima Salim Chamat

Roland A Newman

Peter Brams

Cheryl Janne Heard

Edward E Walsh

Li-Zhen Pan

Novel human monoclonal antibodies, and their corresponding nucleic acid sequences having high affinity for the human RSV-F protein are provided.

Neutralizing high affinity human monoclonal antibodies specific to RSV

A method of detecting RSV (Respiratory Syncytial Virus) in an analyte using high affinity human monoclonal antibodies is provided.

A method of obtaining high affinity human monoclonal antibodies having a Kd of .ltoreq.2.times.10.sup.-9 molar in SCID mice is provided.

A method of treating or preventing RSV infection by the administration of high affinity human monoclonal antibodies having a Kd of about 2.times.10.sup.-9 to 10.sup.-10 molar is provided.

A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein about 2.times.10.sup.-9 to 10.sup.-10 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.

Growing community of inventors

San Diego, CA, United States of America

Soulaima Salim Chamat